Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Cytosorbents (CTSO) FCF Margin (2016 - 2026)

Cytosorbents filings provide 15 years of FCF Margin readings, the most recent being 53.42% for Q4 2025.

  • On a quarterly basis, FCF Margin fell 3010.0% to 53.42% in Q4 2025 year-over-year; TTM through Dec 2025 was 33.84%, a 672.0% increase, with the full-year FY2025 number at 33.84%, up 672.0% from a year prior.
  • FCF Margin hit 53.42% in Q4 2025 for Cytosorbents, down from 27.35% in the prior quarter.
  • In the past five years, FCF Margin ranged from a high of 13.37% in Q2 2021 to a low of 101.59% in Q1 2022.
  • Median FCF Margin over the past 5 years was 53.83% (2025), compared with a mean of 52.14%.
  • Biggest five-year swings in FCF Margin: crashed -7561bps in 2022 and later skyrocketed 6330bps in 2023.
  • Cytosorbents' FCF Margin stood at 84.7% in 2021, then surged by 32bps to 57.71% in 2022, then decreased by -30bps to 75.02% in 2023, then skyrocketed by 69bps to 23.32% in 2024, then plummeted by -129bps to 53.42% in 2025.
  • The last three reported values for FCF Margin were 53.42% (Q4 2025), 27.35% (Q3 2025), and 16.09% (Q2 2025) per Business Quant data.